Chlorthalidone and HCTZ Impacts on Platelet Activation

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This will be a randomized, double-blinded, three-period crossover study of platelet activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis is that CTD has different effects on platelet activation and aggregation than HCTZ.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Creighton University
• Collaborator: Dialysis Clinic, Inc.
• Treatments: Aspirin; Chlorthalidone; Hydrochlorothiazide

Criteria

Inclusion Criteria:

• Men or women age 19 or older

• Not currently taking any routinely scheduled prescription or over the counter medications or herbal supplements

• No use of aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol, dipyridamole, NSAID medications, or herbal supplements within the previous 7 days and able to refrain from use during the study period

• Systolic blood pressure > 110 mmHg and diastolic blood pressure > 60 mmHg

• Non-smoker

Exclusion Criteria:

• Previous adverse reaction or allergy to HCTZ, CTD, or ASA

• Severe sulfonamide hypersensitivity (anaphylaxis or Stevens-Johnson syndrome)

• Diagnosis of any chronic disease or condition

• History of gout or hyperuricemia

• History of pancreatitis

• History of systemic lupus erythematosus (SLE)

• History of hypokalemia requiring treatment

• Pregnant or planning to become pregnant during the study period

• Breastfeeding

• History of hypotension

• History of gastrointestinal bleeding